Mylab is developing a service that supports treatment of breast cancer patients: the service interprets laboratory results automatically and delivers them rapidly both to patients and to the treatment unit.
The service is intended for women who receive chemotherapy after surgery. Before each treatment session, patients will undergo laboratory tests to determine whether the treatment can be carried out as planned.
Patients are informed via SMS whether their treatment will be carried out as planned or whether they need to be contacted with further instructions. A nurse only needs to call those patients whose lab results differ from what was expected, explains Customer Manager Tiina Mäkinen at Mylab.
The treatment units receive an alert list of any deviating results and any patients who missed their tests for some reason. In addition, the patients receive a text message reminder of their scheduled lab appointments.
Approximately 3,500 men are already included in mobile PSA monitoring
A corresponding service is already available for men with prostate cancer who have regular PSA follow-ups. They also quickly receive information via SMS about whether their result was normal or whether the treatment unit will contact them soon.
Mobile PSA monitoring already covers approximately 3,300 patients in the Uusimaa region and 200 patients in the Varsinais-Suomi region. The service includes separate monitoring criteria for patients who have had surgery, received radiation treatment, or are receiving hormonal therapy. It is also suitable for monitoring patients whose prostate cancer does not require active treatment.
It is important for cancer patients to receive their lab results quickly. The service also enables nurses to focus on essential tasks, in other words, treating patients whose lab tests returned deviating results.
The goal is to use the treatment units’ resources more efficiently and to increase patient satisfaction, Tiina Mäkinen says.
Treatment units need new services
Mylab’s CEO Samuli Niiranen emphasizes that the new services are being developed in close cooperation with medical specialists, such as oncologists and urologists. Physicians and other health care professionals who treat patients have also indicated the need for these services.
We are currently in the process of developing corresponding services for following up with intestinal cancer patients and with patients with inflammatory bowel disease who undergo laboratory tests before pharmaceutical treatment at the hospital, Niiranen says.
Mylab is also developing smart transfer of results in basic health care, such as a text message service for INR self-management of patients on warfarin.
The article was first published as an advertorial in the Lääkärilehti magazine 1–2 2018.